Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma.

Kajiyama H, Suzuki S, Yoshikawa N, Tamauchi S, Shibata K, Kikkawa F.

J Gynecol Oncol. 2020 Jan 8. doi: 10.3802/jgo.2020.31.e47. [Epub ahead of print]

2.

Plasma-activated medium promotes autophagic cell death along with alteration of the mTOR pathway.

Yoshikawa N, Liu W, Nakamura K, Yoshida K, Ikeda Y, Tanaka H, Mizuno M, Toyokuni S, Hori M, Kikkawa F, Kajiyama H.

Sci Rep. 2020 Jan 31;10(1):1614. doi: 10.1038/s41598-020-58667-3.

3.

Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.

Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H.

Int J Clin Oncol. 2020 Jan 24. doi: 10.1007/s10147-019-01610-y. [Epub ahead of print]

PMID:
31974683
4.

Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments.

Sassa N, Yokoyama Y, Nishida Y, Yamada S, Uchida H, Kajiyama H, Nagino M, Kodera Y, Gotoh M.

Int J Clin Oncol. 2020 Jan 16. doi: 10.1007/s10147-020-01620-1. [Epub ahead of print]

PMID:
31950376
5.

Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.

Yoshihara M, Kajiyama H, Yokoi A, Sugiyama M, Koya Y, Yamakita Y, Liu W, Nakamura K, Moriyama Y, Yasui H, Suzuki S, Yamamoto Y, Ricciardelli C, Nawa A, Shibata K, Kikkawa F.

Int J Cancer. 2020 Apr 15;146(8):2268-2280. doi: 10.1002/ijc.32854. Epub 2020 Jan 24.

PMID:
31904865
6.

Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.

Yoshida K, Kajiyama H, Inami E, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Shibata K, Nawa A, Kikkawa F.

In Vivo. 2020 Jan-Feb;34(1):109-116. doi: 10.21873/invivo.11751.

7.

Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~.

Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Mizuno K, Yamamuro O, Nagasaka T, Shibata K, Kikkawa F.

BMC Cancer. 2019 Dec 19;19(1):1235. doi: 10.1186/s12885-019-6432-4.

8.

Is standard radical surgery necessary for elderly patients with early-stage epithelial ovarian carcinoma? ~Propensity score matched analysis~.

Kajiyama H, Yoshihara M, Tamauchi S, Yoshikawa N, Niimi K, Suzuki S, Shibata K, Kikkawa F.

Jpn J Clin Oncol. 2019 Dec 14. pii: hyz194. doi: 10.1093/jjco/hyz194. [Epub ahead of print]

PMID:
31837651
9.

How do doctors choose treatment for older gynecological cancer patients? A Japanese Gynecologic Oncology Group survey of gynecologic oncologists.

Yamamoto M, Yoshida Y, Itani Y, Sato S, Futagami M, Sakai H, Kajiyama H, Fujimura M, Aoki Y.

Int J Clin Oncol. 2019 Nov 14. doi: 10.1007/s10147-019-01574-z. [Epub ahead of print]

PMID:
31728682
10.

Prognostic impact of pelvic and para-aortic lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis.

Yoshihara M, Kajiyama H, Tamauchi S, Iyoshi S, Yokoi A, Suzuki S, Kawai M, Nagasaka T, Takahashi K, Matsui S, Kikkawa F.

Jpn J Clin Oncol. 2020 Feb 17;50(2):145-151. doi: 10.1093/jjco/hyz163.

PMID:
31688935
11.

Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.

Shimbo A, Kajiyama H, Tamauchi S, Yoshikawa N, Ikeda Y, Nishino K, Suzuki S, Niimi K, Sakata J, Kikkawa F.

Oncol Rep. 2019 Dec;42(6):2323-2332. doi: 10.3892/or.2019.7352. Epub 2019 Oct 3.

12.

Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis.

Yoshihara M, Kajiyama H, Tamauchi S, Suzuki S, Takahashi K, Matsui S, Kikkawa F.

J Gynecol Oncol. 2019 Nov;30(6):e102. doi: 10.3802/jgo.2019.30.e102.

13.

Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma.

Yoshida K, Yoshikawa N, Shirakawa A, Niimi K, Suzuki S, Kajiyama H, Kikkawa F.

J Gynecol Oncol. 2019 Nov;30(6):e85. doi: 10.3802/jgo.2019.30.e85.

14.

The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer.

Yoshida K, Kajiyama H, Yoshihara M, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Niimi K, Suzuki S, Kikkawa F.

Int J Clin Oncol. 2020 Feb;25(2):384-390. doi: 10.1007/s10147-019-01551-6. Epub 2019 Sep 24.

PMID:
31552530
15.

Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age.

Hanatani M, Yoshikawa N, Yoshida K, Tamauchi S, Ikeda Y, Nishino K, Niimi K, Suzuki S, Kawai M, Kajiyama H, Kikkawa F.

Int J Clin Oncol. 2020 Jan;25(1):187-194. doi: 10.1007/s10147-019-01550-7. Epub 2019 Sep 20.

PMID:
31541363
16.

CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.

Yasui H, Kajiyama H, Tamauchi S, Suzuki S, Peng Y, Yoshikawa N, Sugiyama M, Nakamura K, Kikkawa F.

Clin Exp Metastasis. 2020 Feb;37(1):145-158. doi: 10.1007/s10585-019-09993-y. Epub 2019 Sep 21.

PMID:
31541326
17.

Oxidative stress-dependent and -independent death of glioblastoma cells induced by non-thermal plasma-exposed solutions.

Tanaka H, Mizuno M, Katsumata Y, Ishikawa K, Kondo H, Hashizume H, Okazaki Y, Toyokuni S, Nakamura K, Yoshikawa N, Kajiyama H, Kikkawa F, Hori M.

Sci Rep. 2019 Sep 20;9(1):13657. doi: 10.1038/s41598-019-50136-w.

18.

The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.

Sato S, Yamamoto E, Niimi K, Ino K, Nishino K, Suzuki S, Kotani T, Kajiyama H, Kikkawa F.

Int J Clin Oncol. 2020 Jan;25(1):203-209. doi: 10.1007/s10147-019-01540-9. Epub 2019 Sep 13.

PMID:
31520175
19.

Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting.

Kajiyama H, Yoshihara M, Tamauchi S, Yoshikawa N, Suzuki S, Kikkawa F.

Eur J Obstet Gynecol Reprod Biol X. 2019 Jun 12;4:100071. doi: 10.1016/j.eurox.2019.100071. eCollection 2019 Oct.

20.

The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer.

Shimizu Y, Kajiyama H, Yoshida K, Tamauchi S, Nakanishi T, Kikkawa F.

J Obstet Gynaecol Res. 2019 Dec;45(12):2435-2439. doi: 10.1111/jog.14112. Epub 2019 Aug 29.

PMID:
31468618
21.

Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background.

Yoshida K, Yokoi A, Kagawa T, Oda S, Hattori S, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Shibata K, Kajiyama H, Yokoi T, Kikkawa F.

Carcinogenesis. 2019 Dec 31;40(12):1435-1444. doi: 10.1093/carcin/bgz135.

PMID:
31353396
22.

Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.

Sekiya A, Suzuki S, Tanaka A, Hattori S, Shimizu Y, Yoshikawa N, Koya Y, Kajiyama H, Kikkawa F.

Int J Oncol. 2019 Sep;55(3):755-765. doi: 10.3892/ijo.2019.4845. Epub 2019 Jul 17.

PMID:
31322193
23.

Relationship between preexisting mental disorders and prognosis of gynecologic cancers: A case-control study.

Tamauchi S, Kajiyama H, Moriyama Y, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Niimi K, Suzuki S, Kikkawa F.

J Obstet Gynaecol Res. 2019 Oct;45(10):2082-2087. doi: 10.1111/jog.14053. Epub 2019 Jul 18.

PMID:
31321830
24.

Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database.

Kajiyama H, Suzuki S, Utsumi F, Nishino K, Niimi K, Mizuno M, Yoshikawa N, Kawai M, Oguchi H, Mizuno K, Yamamuro O, Shibata K, Nagasaka T, Kikkawa F.

Nagoya J Med Sci. 2019 May;81(2):193-198. doi: 10.18999/nagjms.81.2.193.

25.

Long-term oncologic outcome and its prognostic indicators in reproductive-age women with ovarian clear-cell carcinoma.

Kajiyama H, Suzuki S, Yoshikawa N, Niimi K, Kawai M, Shibata K, Kikkawa F.

Arch Gynecol Obstet. 2019 Sep;300(3):717-724. doi: 10.1007/s00404-019-05203-y. Epub 2019 Jun 4.

PMID:
31165243
26.

Osteomyelitis due to methicillin-resistant Staphylococcus aureus successfully treated by an oral combination of minocycline and trimethoprim-sulfamethoxazole.

Sato K, Yazawa H, Ikuma D, Maruyama T, Kajiyama H, Mimura T.

SAGE Open Med Case Rep. 2019 Apr 9;7:2050313X19841465. doi: 10.1177/2050313X19841465. eCollection 2019.

27.

Estrogen producing ovarian fibrosarcoma: A case report.

Miura M, Suzuki S, Shibata K, Kajiyama H, Kikkawa F.

Nagoya J Med Sci. 2019 Feb;81(1):171-176. doi: 10.18999/nagjms.81.1.171.

28.

Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma.

Kajiyama H, Suzuki S, Utsumi F, Yoshikawa N, Nishino K, Ikeda Y, Niimi K, Yamamoto E, Kawai M, Shibata K, Nagasaka T, Kikkawa F.

Int J Clin Oncol. 2019 Aug;24(8):950-956. doi: 10.1007/s10147-019-01438-6. Epub 2019 Apr 2.

PMID:
30941534
29.

Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary.

Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Shibata K, Nagasaka T, Kikkawa F.

Int J Gynecol Cancer. 2019 Jun;29(5):910-915. doi: 10.1136/ijgc-2018-000142. Epub 2019 Mar 5.

PMID:
30839284
30.

Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer.

Kajiyama H, Suzuki S, Niimi K, Tamauchi S, Kawai M, Nagasaka T, Shibata K, Kikkawa F.

Int J Clin Oncol. 2019 Jul;24(7):857-862. doi: 10.1007/s10147-019-01416-y. Epub 2019 Feb 15.

PMID:
30771039
31.

Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis.

Kitagawa A, Tsuboi N, Yokoe Y, Katsuno T, Ikeuchi H, Kajiyama H, Endo N, Sawa Y, Suwa J, Sugiyama Y, Hachiya A, Mimura T, Hiromura K, Maruyama S.

Kidney Int. 2019 Mar;95(3):680-692. doi: 10.1016/j.kint.2018.10.025. Epub 2019 Jan 31.

PMID:
30712924
32.

Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study.

Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Nagasaka T, Kikkawa F.

Eur J Obstet Gynecol Reprod Biol. 2019 Mar;234:131-136. doi: 10.1016/j.ejogrb.2019.01.009. Epub 2019 Jan 17.

PMID:
30685661
33.

Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?

Yoshida K, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F.

Int J Clin Oncol. 2019 May;24(5):567-574. doi: 10.1007/s10147-018-1376-2. Epub 2019 Jan 5.

PMID:
30612268
34.

Endometriosis and cancer.

Kajiyama H, Suzuki S, Yoshihara M, Tamauchi S, Yoshikawa N, Niimi K, Shibata K, Kikkawa F.

Free Radic Biol Med. 2019 Mar;133:186-192. doi: 10.1016/j.freeradbiomed.2018.12.015. Epub 2018 Dec 15. Review.

PMID:
30562557
35.

Non-thermal plasma-activated medium modified metabolomic profiles in the glycolysis of U251SP glioblastoma.

Kurake N, Ishikawa K, Tanaka H, Hashizume H, Nakamura K, Kajiyama H, Toyokuni S, Kikkawa F, Mizuno M, Hori M.

Arch Biochem Biophys. 2019 Feb 15;662:83-92. doi: 10.1016/j.abb.2018.12.001. Epub 2018 Dec 5.

PMID:
30528778
36.

PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.

Peng Y, Kajiyama H, Yuan H, Nakamura K, Yoshihara M, Yokoi A, Fujikake K, Yasui H, Yoshikawa N, Suzuki S, Senga T, Shibata K, Kikkawa F.

Cancer Lett. 2019 Feb 1;442:181-192. doi: 10.1016/j.canlet.2018.10.027. Epub 2018 Oct 26.

PMID:
30429105
37.

Molecular mechanisms of non-thermal plasma-induced effects in cancer cells.

Tanaka H, Mizuno M, Ishikawa K, Toyokuni S, Kajiyama H, Kikkawa F, Hori M.

Biol Chem. 2018 Dec 19;400(1):87-91. doi: 10.1515/hsz-2018-0199. Review.

PMID:
30291778
38.

Hematopoietic lineage cell-specific protein 1 (HS1), a hidden player in migration, invasion, and tumor formation, is over-expressed in ovarian carcinoma cells.

Koya Y, Liu W, Yamakita Y, Senga T, Shibata K, Yamashita M, Nawa A, Kikkawa F, Kajiyama H.

Oncotarget. 2018 Aug 24;9(66):32609-32623. doi: 10.18632/oncotarget.25975. eCollection 2018 Aug 24.

39.

Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study.

Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F.

Am J Obstet Gynecol. 2018 Oct;219(4):385.e1-385.e7. doi: 10.1016/j.ajog.2018.07.021. Epub 2018 Aug 4.

40.

Fertility-sparing surgery of malignant transformation arising from mature cystic teratoma of the ovary.

Yoshikawa N, Teshigawara T, Ikeda Y, Nishino K, Sakata J, Utsumi F, Niimi K, Sekiya R, Suzuki S, Kawai M, Shibata K, Kikkawa F, Kajiyama H.

Oncotarget. 2018 Jun 8;9(44):27564-27573. doi: 10.18632/oncotarget.25548. eCollection 2018 Jun 8.

41.

The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.

Yoshida K, Suzuki S, Sakata J, Utsumi F, Niimi K, Yoshikawa N, Nishino K, Shibata K, Kikkawa F, Kajiyama H.

Oncol Lett. 2018 Jul;16(1):515-521. doi: 10.3892/ol.2018.8610. Epub 2018 May 2.

42.

Dengue fever during pregnancy.

Tien Dat T, Kotani T, Yamamoto E, Shibata K, Moriyama Y, Tsuda H, Yamashita M, Kajiyama H, Duc Thien Minh D, Quang Thanh L, Kikkawa F.

Nagoya J Med Sci. 2018 May;80(2):241-247. doi: 10.18999/nagjms.80.2.241.

43.

Hematopoietic lineage cell-specific protein 1 immunoreactivity indicates an increased risk of poor overall survival in patients with ovarian carcinoma.

Liu W, Kajiyama H, Shibata K, Koya Y, Senga T, Kikkawa F.

Oncol Lett. 2018 Jun;15(6):9406-9412. doi: 10.3892/ol.2018.8493. Epub 2018 Apr 13.

44.

KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells.

Kawai Y, Shibata K, Sakata J, Suzuki S, Utsumi F, Niimi K, Sekiya R, Senga T, Kikkawa F, Kajiyama H.

Oncol Rep. 2018 Jul;40(1):195-205. doi: 10.3892/or.2018.6401. Epub 2018 Apr 25.

45.

Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model.

Ohara Y, Chew SH, Misawa N, Wang S, Somiya D, Nakamura K, Kajiyama H, Kikkawa F, Tsuyuki Y, Jiang L, Yamashita K, Sekido Y, Lipson KE, Toyokuni S.

Oncotarget. 2018 Apr 6;9(26):18494-18509. doi: 10.18632/oncotarget.24892. eCollection 2018 Apr 6.

46.

Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.

Hamada M, Takayama T, Shibata T, Hiratate A, Takahashi M, Yashiro M, Takayama N, Okumura-Kitajima L, Koretsune H, Kajiyama H, Naruse T, Kato S, Takano H, Kakinuma H.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1725-1730. doi: 10.1016/j.bmcl.2018.04.039. Epub 2018 Apr 16.

PMID:
29681433
47.

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas.

Nakamura K, Kajiyama H, Utsumi F, Suzuki S, Niimi K, Sekiya R, Sakata J, Yamamoto E, Shibata K, Kikkawa F.

Mol Clin Oncol. 2018 Mar;8(3):499-503. doi: 10.3892/mco.2018.1560. Epub 2018 Jan 19.

48.

The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours.

Kajiyama H, Suzuki S, Yoshihara M, Nishino K, Yoshikawa N, Utsumi F, Niimi K, Mizuno M, Kawai M, Oguchi H, Mizuno K, Yamamuro O, Nagasaka T, Shibata K, Kikkawa F.

Oncotarget. 2018 Jan 4;9(5):6298-6307. doi: 10.18632/oncotarget.23921. eCollection 2018 Jan 19.

49.

A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence.

Yoshida K, Kajiyama H, Utsumi F, Niimi K, Sakata J, Suzuki S, Shibata K, Kikkawa F.

Mol Clin Oncol. 2018 Feb;8(2):281-285. doi: 10.3892/mco.2017.1530. Epub 2017 Dec 8.

50.

Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis.

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovský J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K.

Ann Rheum Dis. 2018 Apr;77(4):602-611. doi: 10.1136/annrheumdis-2017-212149. Epub 2018 Jan 13.

PMID:
29331962

Supplemental Content

Loading ...
Support Center